Patients receiving Mounjaro, also called Zepbound in the US, lost an average of 22.5 per cent of their weight in phase three ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in decades on Friday after the results from a late-stage trial showed that the Danish company's new weight-loss drug ...

U.S. stock futures are pointing lower as investors watch for a potential partial government shutdown; economists expect the ...

Novo Nordisk's trial for its obesity drug CagriSema resulted in a lower-than-expected weight loss of 22.7%, impacting its market value. Despite these results, Novo remains optimistic about further ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

FedEx Corp shares increased 9% in Friday's premarket session after the package delivery company outlined plans to spin off its FedEx Freight trucking business Eli Lilly s ...

One out of 20 prescriptions written in the U.S. is for a GLP-1 drug. US doctors write billions of prescriptions each year.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...

Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.